Clinical Studies for
FFR and FFRangio
Read below to learn how routine use of FFRangio can reduce unnecessary stenting, improves outcomes, and reduces costs compared to angiography alone.Read the Fast-FFR Pivotal Trial
FFRangio Clinical Evidence
FFRangio is supported by strong clinical evidence proving excellent diagnostic performance vs. invasive wire based FFR.
Clinical Evidence on FFR for PCI Decision-Making
Angiography alone is a poor predictor of physiological significance. Studies show routine use of FFR is proven to improve patient outcomes, cut costs, and reduce unnecessary stenting.
The FAME trial compared FFR-guided PCI decision- making (by pressure wire) versus PCI guided by angiography alone in 1,005 randomized patients with multi-vessel coronary artery disease. Routine measurement of FFR significantly reduced clinical events at 1 year.Read More
FAME Trial Economic Analysis
Economic analysis of the FAME Trial revealed that PCI guided by FFR saves costs and improves health outcomes at 1 year compared with angiography guidance. Cost savings are driven by a decrease in stent use during the initial procedure, a decrease in rehospitalization and fewer major adverse cardiac events.Read More
FAME II Trial
The FAME II Trial randomized stable CAD patients with FFR ≤ 0.80 to PCI + medical therapy or medical therapy alone. Enrollment was halted early after 1,220 patientsRead More
FFR in Clinical Guidelines
Consistent use of FFR is supported by worldwide clinical guidelines.
Guideline for Percutaneous Coronary InterventionRead More
Appropriate Use Criteria for Coronary Revascularization in Patients with Acute Coronary SyndromesRead More
Appropriate Use Criteria for Coronary Revascularization in Patients with Stable Ischemic Heart DiseaseRead More
Guidelines on Myocardial RevascularizationRead More